Catalent, Inc. (NYSE:CTLT – Get Rating) has earned a consensus recommendation of “Hold” from the thirteen research firms that currently cover the stock, Marketbeat Ratings reports. One equity research analyst gave the stock a sell rating, three gave the company a hold rating and five gave the company a buy rating. The 1-year average price target among brokers who have issued ratings on the stock in the past year is $92.80.

Several analysts have recently released reports on CTLT shares. Morgan Stanley cut its price target on Catalent shares from $120.00 to $81.00 and set an “overweight” rating for the company in a Thursday, Nov. 3 research report. TheStreet downgraded Catalent’s shares from a “b-” rating to a “c+” rating in a Friday, October 28 research report. Robert W. Baird cut his price target on Catalent shares from $123.00 to $75.00 in a Wednesday, Nov. 2, research report. KeyCorp cut its price target on Catalent shares from $125.00 to $85.00 and set an “overweight” rating on the stock in a Wednesday, Nov. 2, report. Finally, StockNews.com downgraded Catalent’s shares from a “hold” rating to a “sell” rating in a report on Saturday, Nov. 5.

Insider Trading at Catalent

Separately, SVP Michael J. Grippo sold 2,451 shares of Catalent in a trade on Monday, October 31. The stock was sold at an average price of $65.83, for a total transaction of $161,349.33. Following the sale, the senior vice president now directly owns 17,792 shares of the company, valued at approximately $1,171,247.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Separately, insider Thomas W. Hawkeswood sold 930 shares of the company in a trade dated Monday, October 10. The stock was sold at an average price of $77.46, for a total value of $72,037.80. Following the sale, the insider now directly owns 5,364 shares of the company, valued at approximately $415,495.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Additionally, SVP Michael J. Grippo sold 2,451 shares of the company in a trade dated Monday, October 31. The shares were sold at an average price of $65.83, for a total value of $161,349.33. Following the completion of the sale, the senior vice president now owns 17,792 shares of the company, valued at $1,171,247.36. The disclosure of this sale can be found here. Insiders sold 17,055 shares of the company worth $1,642,356 in the past ninety days. Insiders of the company hold 0.58% of the shares of the company.

Institutional investors weigh in on Catalent

A number of hedge funds and other institutional investors have recently increased or reduced their stake in CTLT. Hilton Capital Management LLC increased its position in Catalent shares by 26.4% during the third quarter. Hilton Capital Management LLC now owns 2,970 shares of the company valued at $215,000 after purchasing an additional 620 shares during the period. WINTON GROUP Ltd increased its position in Catalent shares by 143.0% during the third quarter. WINTON GROUP Ltd now owns 8,986 shares of the company valued at $650,000 after purchasing an additional 5,288 shares during the period. ExodusPoint Capital Management LP purchased a new equity stake in Catalent during the third quarter worth approximately $4,629,000. Dimensional Fund Advisors LP increased its position in Catalent shares by 15.3% during the third quarter. Dimensional Fund Advisors LP now owns 1,093,061 shares of the company valued at $79,119,000 after purchasing an additional 144,917 shares during the period. Finally, Seven Eight Capital LP purchased a new equity stake in Catalent during the third quarter valued at approximately $493,000. 90.54% of the shares are currently held by institutional investors.

Catalent Stock Performance

NYSE: CTLT opened at $47.18 on Friday. The company has a fifty-day moving average of $72.52 and a 200-day moving average of $92.80. Catalent has a 12-month low of $40.72 and a 12-month high of $136.13. The company has a quick ratio of 2.08, a current ratio of 2.86 and a debt ratio of 0.87. The company has a market capitalization of $8.49 billion, a P/E ratio of 20.16, a P/E/G ratio of 1.83 and a beta of 1.30.

Catalent (NYSE:CTLT – Get Rating) last released its quarterly results on Tuesday, November 1. The company reported earnings per share (EPS) of $0.25 for the quarter, missing the consensus estimate of $0.49 per ($0.24). Catalent had a net margin of 8.83% and a return on equity of 12.55%. The company posted revenue of $1.02 billion in the quarter, versus analyst estimates of $1.06 billion. As a group, sell-side analysts expect Catalent to post 3.12 EPS for the current year.

About Catalent

(Get a rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for pharmaceuticals, protein biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development and manufacturing services for soft gel capsules for use in a range of customer products, such as prescription drugs, over-the-counter drugs, dietary supplements, dose cosmetics unitary and medicines for animal health. preparations.

Read more

Analyst Recommendations for Catalent (NYSE: CTLT)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Catalent, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and Catalent wasn’t on the list.

While Catalent currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here